OMB #: 0925-0476 									                     Exp. Date: 07/31/2009	

Survey Questions for Assay Providers

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0476). Do not return the completed form to this address. 

A)	Network Customer Satisfaction: How well is the network serving the needs of the community?

1.	What is the satisfaction level of assay providers with the MLSCN/MLPCN?
a)	Did the experience with MLSCN/MLPCN result in new publications?
b)	Did the experience with MLSCN/MLPCN result in new grants?
c)	How do your experiences with the MLSCN/MLPCN compare to those at non-MLSCN/MLPCN centers?

2.	What are the challenges for entering assays into the ML?
a)	What are the core features of the MLSCN/MLPCN that must be maintained or enhanced? 
b)	What are the challenges (or your thoughts) with the intellectual property (IP) & data sharing policy?
c)	What are the challenges (or your thoughts) with the requirement for assays to be HTS-ready or nearly ready?
d)	What are the challenges (or your thoughts) with the availability of funding for reagent production/secondary screening?
e)	What are the challenges (or your thoughts) with the amount of time & effort required to write an application for access to the MLSCN/MLPCN?
f)	What are the challenges (or your thoughts) with the amount of time from submission of application until results are obtained from screening center?
g)	What specific approaches or concepts would address any of the challenges above?

3.	What capabilities would you like the network to offer that it does not?
a)	What area(s) of biology do you feel have not been adequately explored with small molecules (target classes or cellular phenotypes)?
b)	Are there other capabilities that you would like the network to offer that it does not have?

B)	Production Centers: What has been the productivity of the centers (individually & as a network)?
1.	Is MLPCN center infrastructure fully operational, as prescribed by the goals of RFA RM-08-005?
a)	What is the number of collaborations within, across, and outside of the Centers?

C)	Data Dissemination: Has data dissemination been effective?
1.	Do biologists actively use & value PubChem?
a)	Have there been improvements in the retrieval & browsing tools for PubChem?
b)	What is your level of satisfaction with PubChem?

D)	Probes & Probe Reports: What is the usefulness of the probes produced?

1.	Do the probes produced reflect the state of the art in probe development/production?
a)	What is the current or potential application of MLSCN/MLPCN data and probes to your research? 
b)	What is the current or potential application of MLSCN/MLPCN data and probes to the broader research community? 

2.	What number of probes has been advanced after leaving the MLPCN? 

3.	How many publications came from the probes: 
a)	Directly (i.e., assay provider)?
b)	Indirectly (i.e., all other non-ML providers)?

4.	How many new grant proposals emerged from the program (e.g., for further optimization or use of the probes)? 

5.	How many new licenses and patents emerging from the program have been applied for/granted?